Edesa Biotech gains FDA clearance to expand Phase 2 vitiligo trial

U.S. trial sites can join an ongoing vitiligo study after Edesa Biotech, Inc. NASDAQEDSA reported FDA clearance of its investigational new drug application on Thursday. The Phase 2 study will test EB06 against placebo in up to 80 adults, with topline results expected in the fourth quarter of 2027.

The Oct. 15 release says Canadian recruitment is underway and the first U.S. sites are expected to begin enrolling patients in the first quarter of 2027. The clearance allows U.S. clinical testing, while EB06's safety and efficacy remain under evaluation.

Edesa is a small Canadian clinical-stage drug developer focused on inflammatory and immune diseases, with programs in dermatology and respiratory medicine.

Shares closed at US$2.67, up 0.75 per cent, in Nasdaq trading at 4 p.m. EDT on Oct. 15, according to Google Finance NASDAQEDSA.

The Trial Measures Facial Scores At Week 28

The double-blind study will assign participants equally to EB06 or placebo, with treatment every two weeks through week 22. Its primary endpoint is the mean percentage change from baseline in the Facial Vitiligo Area Scoring Index at week 28.

That endpoint measures the average change in the facial vitiligo score. Secondary and exploratory measures include facial and total-body scoring benchmarks, safety, tolerability, pharmacokinetics and immunogenicity, which assess drug behaviour in the body and immune responses.

EB06 targets CXCL10, a signalling protein implicated in vitiligo. Edesa says blocking it is intended to interrupt immune-cell recruitment and the loss of melanocytes, the cells responsible for skin pigmentation.

"EB06 is currently formulated for intravenous administration, with a subcutaneous formulation anticipated to be ready for follow-on clinical evaluation," Edesa said in its Oct. 15 release.

Edesa said EB06 was generally safe and well tolerated in three earlier clinical studies involving 65 subjects. The Oct. 15 announcement reports permission to expand recruitment, without reporting efficacy results from the ongoing vitiligo study.

Competing Programs Have Reached Later Stages

Incyte Corporation NASDAQINCY reported on April 28 that its Opzelura cream generated US$143 million in first-quarter net sales across atopic dermatitis and vitiligo. That combined figure does not isolate vitiligo revenue; the same update reported positive Phase 3 results for oral povorcitinib in nonsegmental vitiligo.

AbbVie Inc. NYSEABBV said on Oct. 1 that Rinvoq was approved in the European Union for eligible adults and adolescents with nonsegmental vitiligo and remained under FDA review for that use. Its update described continued repigmentation through week 76 in open-label extensions of its Phase 3 studies.

Those dated disclosures put Edesa's placebo-controlled study alongside a marketed cream and later-stage systemic programs. They do not provide a direct comparison with EB06, whose trial uses its own population, treatment schedule and endpoint.

Edesa reported US$10.3 million in cash and equivalents at June 30, before its subsequent financing announcement. Research and development expenses for the quarter ended June 30 rose to US$4 million from US$0.9 million, primarily reflecting EB06 manufacturing and trial preparations plus unallocated research costs, partly offset by lower respiratory-program spending.

In its Aug. 19 pricing announcement, Edesa said a public offering was expected to generate US$25 million gross, with net proceeds intended for general corporate purposes. That notice described an expected closing; the Oct. 15 trial update supplied neither an updated cash balance nor a cash runway estimate.

The next operational milestone is the planned start of U.S. enrolment in the first quarter of 2027. The fourth-quarter 2027 topline results are expected to show how EB06 performs against placebo on the trial's primary facial-score endpoint.